Elicera Therapeutics AB (publ) (ELIC.ST)
SEK 3.25
(6.21%)
SEK 3.25
(6.21%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 13.77 Million SEK | 1.95% |
| 2022 | 13.5 Million SEK | 440.31% |
| 2021 | 2.5 Million SEK | 6.22% |
| 2020 | 2.35 Million SEK | 58742.88% |
| 2019 | 4000.00 SEK | 0.0% |
| 2018 | 4000.00 SEK | 0.0% |
| 2017 | 4000.00 SEK | -96.79% |
| 2016 | 124.6 Thousand SEK | -66.03% |
| 2015 | 366.76 Thousand SEK | -38.55% |
| 2014 | 596.87 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 7.97 Million SEK | -18.6% |
| 2024 Q1 | 9.79 Million SEK | -28.89% |
| 2023 FY | 13.77 Million SEK | 1.95% |
| 2023 Q1 | 13.31 Million SEK | -1.46% |
| 2023 Q4 | 13.77 Million SEK | 96.73% |
| 2023 Q3 | 7 Million SEK | -52.81% |
| 2023 Q2 | 14.83 Million SEK | 11.45% |
| 2022 Q2 | 1.52 Million SEK | -15.22% |
| 2022 Q3 | 4.55 Million SEK | 198.12% |
| 2022 Q4 | 13.5 Million SEK | 196.28% |
| 2022 FY | 13.5 Million SEK | 440.31% |
| 2022 Q1 | 1.8 Million SEK | -27.85% |
| 2021 Q1 | 1.4 Million SEK | -40.42% |
| 2021 FY | 2.5 Million SEK | 6.22% |
| 2021 Q4 | 2.5 Million SEK | 60.62% |
| 2021 Q3 | 1.55 Million SEK | -75.9% |
| 2021 Q2 | 6.45 Million SEK | 360.5% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 Q4 | 2.35 Million SEK | 0.0% |
| 2020 FY | 2.35 Million SEK | 58742.88% |
| 2019 FY | 4000.00 SEK | 0.0% |
| 2018 FY | 4000.00 SEK | 0.0% |
| 2017 FY | 4000.00 SEK | -96.79% |
| 2016 FY | 124.6 Thousand SEK | -66.03% |
| 2015 FY | 366.76 Thousand SEK | -38.55% |
| 2014 FY | 596.87 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alzinova AB (publ) | 9.33 Million SEK | -47.589% |
| Amniotics AB (publ) | 10.54 Million SEK | -30.573% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -211.152% |
| BioArctic AB (publ) | 139.5 Million SEK | 90.128% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.12% |
| Genovis AB (publ.) | 98.04 Million SEK | 85.954% |
| LIDDS AB (publ) | 3.75 Million SEK | -266.655% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 88.892% |
| OncoZenge AB (publ) | 1.69 Million SEK | -710.569% |
| Saniona AB (publ) | 86.08 Million SEK | 84.002% |
| Simris Alg AB (publ) | 148.93 Million SEK | 90.753% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 66.295% |
| AcouSort AB (publ) | 10.37 Million SEK | -32.7% |
| Active Biotech AB (publ) | 13.4 Million SEK | -2.773% |
| Camurus AB (publ) | 414.81 Million SEK | 96.68% |
| Cantargia AB (publ) | 54.97 Million SEK | 74.947% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -258.822% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 25.535% |
| Mendus AB (publ) | 51.22 Million SEK | 73.116% |
| Kancera AB (publ) | 17.97 Million SEK | 23.398% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -19.039% |
| Lipum AB (publ) | 7.53 Million SEK | -82.695% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -166.994% |
| NextCell Pharma AB | 13.68 Million SEK | -0.603% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 97.144% |
| Xintela AB (publ) | 14.01 Million SEK | 1.737% |
| Ziccum AB (publ) | 6.38 Million SEK | -115.585% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -483.789% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 28.138% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 80.833% |
| CombiGene AB (publ) | 4.15 Million SEK | -231.366% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 80.636% |
| Intervacc AB (publ) | 21.68 Million SEK | 36.478% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 87.08% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 60.201% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 48.437% |
| Corline Biomedical AB | 6.78 Million SEK | -102.851% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 77.555% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 14.552% |
| Aptahem AB (publ) | 8.99 Million SEK | -53.054% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 70.178% |
| Fluicell AB (publ) | 8.91 Million SEK | -54.476% |
| Biovica International AB (publ) | 34.76 Million SEK | 60.389% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -18.029% |
| Abliva AB (publ) | 16.78 Million SEK | 17.934% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 93.583% |
| 2cureX AB (publ) | 2.93 Million SEK | -369.219% |
| I-Tech AB | 16.2 Million SEK | 15.017% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 98.839% |
| Cyxone AB (publ) | 4.69 Million SEK | -193.387% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -3.328% |
| Biosergen AB | 5.08 Million SEK | -170.827% |
| Nanologica AB (publ) | 79.32 Million SEK | 82.639% |
| SynAct Pharma AB | 51.83 Million SEK | 73.431% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -73.249% |
| BioInvent International AB (publ) | 90.45 Million SEK | 84.775% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -165.096% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 92.416% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -667.646% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -8.063% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -89.691% |